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Abstract
Alzheimer’s disease (AD) is the most common cause of dementia in the human population, characterized by a spectrum of
neuropathological abnormalities that results in memory impairment and loss of other cognitive processes as well as the
presence of non-cognitive symptoms. Transcriptomic analyses provide an important approach to elucidating the
pathogenesis of complex diseases like AD, helping to figure out both pre-clinical markers to identify susceptible patients
and the early pathogenic mechanisms to serve as therapeutic targets. This study provides the gene expression profile of
postmortem brain tissue from subjects with clinic-pathological AD (Braak IV, V, or V and CERAD B or C; and CDR $1),
preclinical AD (Braak IV, V, or VI and CERAD B or C; and CDR= 0), and healthy older individuals (Braak # II and CERAD 0 or A;
and CDR= 0) in order to establish genes related to both AD neuropathology and clinical emergence of dementia. Based on
differential gene expression, hierarchical clustering and network analysis, genes involved in energy metabolism, oxidative
stress, DNA damage/repair, senescence, and transcriptional regulation were implicated with the neuropathology of AD;
a transcriptional profile related to clinical manifestation of AD could not be detected with reliability using differential gene
expression analysis, although genes involved in synaptic plasticity, and cell cycle seems to have a role revealed by gene
classifier. In conclusion, the present data suggest gene expression profile changes secondary to the development of AD-
related pathology and some genes that appear to be related to the clinical manifestation of dementia in subjects with
significant AD pathology, making necessary further investigations to better understand these transcriptional findings on the
pathogenesis and clinical emergence of AD.
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Introduction
Alzheimer’s disease (AD) is the most frequent dementing
disorder in the elderly and is characterized by a progressive
decline in memory and other cognitive domains [1]. The hallmark
neuropathological lesions in AD are the presence of neuritic
plaques and neurofibrillary tangles, which are secondary to the
deposition of b-amyloid peptide (Ab) and hyperphosphorylated tau
protein [2,3]. The presence of these two lesions is necessary to
definite diagnosis of AD in post-mortem studies [4,5]. The
pathogenic mechanisms that lead to AD are unclear. The most
accepted pathogenic process in AD derives from the ‘‘amyloid
cascades hypothesis’’. In summary, it states that accumulation of
amyloid-b species in the brain, either by increased production or
by reduced protein clearance, leads to several secondary patho-
logical changes in neurons and glial cells culminating in
widespread neurodegeneration (dystrophic neurites and intracel-
lular neurofibrillary tangles) and cell death [6,7].
However, there is a growing body of evidence that suggest the
accumulation of Ab in the brain in cognitively healthy older
subjects. Post-mortem studies showed that a significant proportion
of subjects with neuropathological diagnosis of AD did not have
any evidence of cognitive impairment in the last assessment prior
to death [8,9]. More recently, molecular neuroimaging and CSF
biomarkers studies demonstrated that 20–40% of older subjects
with no cognitive impairment had a significant accumulation of
Ab in the brain [10–14]. The most common explanations to such
findings are that (1) there is a long pre-clinical phase of AD in
which there is the development of brain amyloidosis without
apparent clinical symptoms; (2) there are unknown mechanisms of
neuronal resilience (brain reserve) or cognitive reserve that
protects against the neurotoxic insults related to the amyloidogen-
esis; (3) the amyloidogenesis observed in AD is part of normal
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brain aging and some patients may develop or not the dementia
syndrome of AD as a consequence of other related neurodegen-
erative processes. Of note, labeling these individuals as having pre-
symptomatic AD is a hypothesis, because some of these individuals
will die without ever expressing clinical symptoms. The hypothet-
ical assumption is that asymptomatic individuals with AD
pathological changes would have become symptomatic if they
lived long enough.
The study of brain mRNA expression profile may help to
disentangle some of the molecular mechanisms related to the
development of AD-related pathology and the manifestation of
clinical dementia in these subjects. Previous studies showed
a significant deregulation in the expression of genes related to
the energy metabolism [15], transcriptional and tumor suppressor
responses [16], apoptosis, inflammation [17], cholinergic activity
[18], calcium signaling [19], lipid metabolism [20], and synaptic
dysfunction and neuroplasticity [21,22]. Changes in many of these
biological cascades have been demonstrated in peripheral or brain
samples of patients with AD or at increased risk to develop
dementia [23–31]. In addition, these changes were independent of
disease severity, according to clinical rating scales. Studies using
gene network in this area have contributed to better explore data
produced by those mRNA expression studies [32,33].
Nevertheless, no study to date have addressed whether specific
patterns of gene expression is associated to the development of
AD-related pathology and to the clinical manifestation of de-
mentia in subjects with significant AD pathology. Therefore, the
aims of this study were: (1) to determine which genes and their
biological functions are related to the development of AD
pathology; (2) to determine which genes and their biological
functions are related to the clinical manifestation of dementia in
subjects with significant AD pathology.
Materials and Methods
Sample Characteristics
After death, a trained gerontologist interviewed a knowledgeable
informant who had at least weekly contact with deceased subjects.
Past medical history, cognitive performance and functional status
was determined for each subject [34]. Dementia stage was
ascertained by the Clinical Dementia Rating Scale (CDR) [35].
All informants voluntarily signed an Informed Consent Form and
consented to provide all clinical information requested.
At autopsy, hippocampus was dissected and frozen at 280uC.
Hippocampal specimens were obtained from the Brain Bank of the
Brazilian Aging Brain Study Group [36]. We chose to study only
hippocampal gene expression as this brain region shows the
earliest pathological changes and hippocampal-mediated episodic
memory impairment is the earliest cognitive changes observed in
AD patients [37,38].
Neuropathological examinations were performed using immu-
nohistochemistry according to internationally accepted criteria
[36]. Neurofibrillary tangles (NFTs) and neuritic plaques (NPs)
were assessed by a skilled neuropathologist in accordance with the
Braak and Braak stage system [37], and the Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD) [5],
respectively. Cases with a Braak stage $ IV, or the presence of
moderate or frequent neuritic plaques in one or more neocortical
regions (CERAD = B or C), were classified as meeting criteria for
AD. The neuropathologist was blinded to all clinical information.
Based on pathological and clinical criteria, subjects were
categorized into three groups: I) 9 subjects with neuropathological
AD (Braak $ IV and CERAD = B or C), and clinical dementia
(CDR $1), termed ‘‘clinic-pathological AD’’ (CP-AD); II) 4 subjects
with neuropathological AD (Braak $IV and CERAD = B or C),
and without cognitive impairment (CDR=0), termed ‘‘pathological/
preclinical AD’’ (P-AD); and III) 10 subjects without neuropatho-
logical AD (Braak# II and CERAD 0 or A), and normal cognitive
function (CDR=0), termed ‘‘normal older individuals’’ (N). The
neuropathological and clinical data, and post-mortem interval of
each case can be visualized in Table 1.
This study was approved by the Ethical Board for Research
Project Analysis (CAPPesq) of the University of Sao Paulo Medical
School (research protocol 285/04) and was conducted in
accordance to the Helsinki Declaration.
RNA Isolation and Amplification
Total RNA was isolated from the frozen hippocampus by the
RNeasy Mini kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. RNA purity and yield were de-
termined by UV spectrophotometry for all RNA samples (Table
S1). Quality control was performed using the RNA 6000 Pico
LabChipH kit with a Model 2100 Bioanalyzer (Agilent Technol-
ogies, Waldbronn, Germany). A two-round linear amplification
procedure, based on T7-driven amplification, was performed
following a previously described protocol [39] with some
modifications described below. The total RNA was first denatured
at 70uC for 10 minutes in presence of 200 ng oligo dT (24)-T7
Table 1. Summary of selected cases.
Sample ID Gender Age Braak CERAD CDR PMI
CP-AD1 F 99 V B 3 18.3
CP-AD2 F 82 IV B 2 13.5
CP-AD3 F 86 IV C 1 10.1
CP-AD4 F 83 V A 3 12.1
CP-AD5 M 69 VI C 2 15.0
CP-AD6 F 87 V B 3 17.7
CP-AD7 F 82 V C 2 11.8
CP-AD8 F 77 IV A 3 16.0
CP-AD9 F 83 VI C 3 10.8
P-AD1 F 87 V C 0 11.1
P-AD2 F 85 V C 0 9.6
P-AD3 M 72 VI C 0 11.7
P-AD4 F 86 VI C 0 16.0
N1 F 71 0 0 0 16.1
N2 M 79 I 0 0 8.3
N3 F 81 I 0 0 11.9
N4 M 77 I A 0 6.5
N5 M 57 0 0 0 9.8
N6 F 65 0 0 0 12.7
N7 F 59 0 0 0 14.0
N8 M 89 II 0 0 14.2
N9 F 82 0 0 0 14.8
N10 F 94 II 0 0 12.3
Subjects were divided in three groups according to neuropathological and
clinical criteria: clinic-pathological Alzheimer’s disease (CP-AD), pathological/
preclinical Alzheimer’s disease (P-AD), and normal older individuals (N). Sample
ID, sample identification; Age, age at death in years; F, female; M, male; Braak,
Braak stage; CERAD, Consortium to Establish a Registry for Alzheimers Disease
score; CDR, Clinical Dementia Ratio score; PMI, post-mortem interval in hours.
doi:10.1371/journal.pone.0048751.t001
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primer (59-AAA CGA CGG CCA GTG AAT TGT AAT ACG
ACT CAC TAT AGG CGC T (24)-39; 57 base pairs) and snap
cooled on ice.
Reverse transcription was performed by adding 16 first strand
buffer and 0.01 mol/l dithiothrectol (Invitrogen Life Technology,
Carlsbad, CA, USA), 2 ml diethylpyrocarbonate (DEPC; Sigma, St
Louis, MO, USA) treated water, 40 U rRNasin (Promega,
Madison, WI, USA), 1 mmol/l dNTP (Amersham Biosciences,
Piscataway, NJ, USA), and 400 U SuperScriptTM II Reverse
Transcriptase (Invitrogen Life Technology) to a final volume of
20 ml. The reaction was incubated for 120 minutes at 42uC.
Second-strand synthesis was performed by adding 53 ml of DEPC-
treated water, 20 ml of 56 second strand buffer (Invitrogen Life
Technology), 1 mmol/l dNTP, 1 U RNase H (Invitrogen Life
Technology), 10 U Escherichia coli DNA ligase, and 40 U E. coli
DNA polymerase I (Invitrogen Life Technology) to a final volume
of 100 ml. The reaction was incubated for 2 hours at 16uC. Ten
units of T4 DNA polymerase I (Invitrogen Life Technology) were
added and incubated again at 16uC for 5 minutes.
The double strand cDNA (dscDNA) was stopped by adding
0.05 mol/l EDTA. UltraPureTM Phenol (Invitrogen, Carlsbad,
CA, USA):chloroform:isoamyl alcohol (Merck), at a ratio of
25:24:1 and a pH of 8.0, was used for cDNA purification. The
dscDNA was precipitated with absolute ETOH (Merck) and
resuspended in 10 ml DEPC-treated water. The dscDNAs were
subjected to in vitro transcription using reagents from Ribo-
maxTM Large scale RNA production system T7 kit (Promega), in
accordance with the manufacturer’s recommendation. The
amplified RNA (aRNA) was reverse transcribed into cDNA using
9 mg random hexamer (dN6; Amersham Bio- sciences, Little
Chalfont, UK). cDNA synthesis was continued with the same
conditions used in the first strand of the first round. The second
strand was synthesized using AdvantageH cDNA Polymerase
(Clontech, Mountain View, CA, USA), and purification was
performed in accordance with the methodology cited above.
The aRNA quality, in terms of purity and integrity (Table S1),
was assessed by absorbance at 260/280 nm using a GeneQuant
pro spectrophotometer (Amersham Pharmacia Biotech, Little
Chalfont, UK) and by electrophoresis in 1% UltraPureTM
Agarose (Invitrogen Life Technology) gel, respectively. Only
aRNA samples yielding a minimum of 15 mg and presenting
a smear concentration between 300 and 700 base pairs (which
guarantees high quality hybridization) were further processed. A
total RNA pool of 15 cell lines [40] was amplified following the
same protocol and used as reference sample for microarray
hybridizations.
cDNA Microarrays and Probes
Labeled cDNA was generated in a reverse transcriptase reaction
in the presence of 7 mg of amplified RNA (aRNA), 9 mg of
a random hexamer primer (Invitrogen Life Technologies,
Carlsbad, CA), Cy3- or Cy5-labeled dCTP (Amersham, Bios-
ciences, Little Chalfont, UK), and 400 U SuperScriptTM II
Reverse Transcriptase (Invitrogen Life Technology). The residual
dye was removed using illustra AutoSeqTM G-50 (GE Healthcare,
Little Chalfont, UK). Equal amounts of test and reference cDNA
reverse colored Cy-labeled product were competitively hybridized
against the cDNA probes in a customized cDNA platform with
4,608 ORESTES representing human genes [41]. Dye-swap was
performed for every sample and used as a replicate. Therefore, 46
arrays were utilized in this study –18 arrays for CP-AD group (9
subjects), 8 arrays for P-AD group (4 subjects), and 20 arrays for N
group (10 subjects). Pre-hybridization was carried out in a humid-
ified chamber at 42uC for 6 hours and hybridizations were
performed on a GeneTac Hybridization Station (Genome
Solutions, MI) at 42uC for 16 to 20 hours.
Signal Intensity Capture and Analysis
After hybridization, slides were washed as follows: 26 Saline
Sodium Citrate (SSC) for 10 minutes, 0.16SSC/0.1% SDS for 10
minutes (two times), and 0.16 SSC for 10 minutes (two times) at
37uC. All solutions were pre-heated to 42uC. Hybridized arrays
were scanned on the ScanArrayTM Express (Packard BioScience
Biochip Technologies, Billerica, MA, USA), and Cy5/Cy3 signals
were quantified using the histogram method with ScanArray
Express software (Perkin-Elmer Life Sciences, Boston, MA, USA).
Fluorescent intensities of Cy5 and Cy3 channels on each slide were
subjected to spot filtering and normalization. We first eliminated
all saturated points ($63,000; approximately 16 bits) and
performed a local background subtraction, considering for analysis
only those spots with positives values. Normalization was
performed using locally weighted linear regression within and
across arrays for inter-slide normalization. After normalization,
data for each gene were reported as the logarithm of the
expression ratio used to represent the relative gene expression
levels in the experimental samples. The raw data from hybridiza-
tions and experimental conditions can be obtained at the Gene
Expression Omnibus under accession number GSE13214. A
detailed description of the platform array is available in accession
number GPL1930.
Statistical Analysis
For analysis of genes related to pathological changes, individuals
with AD pathology (CP-AD and P-AD) were compared to
individuals without pathology (N). To identify genes implicated
with clinical manifestation of dementia, individuals who present
AD neuropathology but differ on the clinical status were compared
(CP-AD versus P-AD). For both analyses, we first used Student’s t-
tests with a statistical significance level a=5% and a False
Discovery Rate (FDR) ,0.05 to search for differentially expressed
genes. As we did not achieve significant results using this criteria,
we worked with an a=1% (without FDR). So, Student’s t-tests
were carried out at P#0.01 with 1000 permutations by MEV
(MultiExperiment Viewer – Boston, MA, USA) software [42].
Genes were functionally classified according to biological processes
through Gene Ontology (GO), using FunNet [43]. EntrezGene
numbers were used as a standard transcript accession system. All
genes of our microarray slide were used as reference set to perform
the overrepresentation analysis of the biological GO categories.
Significance of overrepresented biological processes was assessed
using a built-in Fisher’s exact test with a P#0.05 cut-off.
Hierarchical clustering analysis was based on Euclidean distance
and average linkage. Reliability of the clustering was assessed by
the Bootstrap technique using MEV software.
Interaction Networks
To see more properties implicated with the differentially
expressed genes and their partners, we used a network approach.
By querying three human interactome databases (HPRD [44],
MINT [45] and IntAct [46]), a protein-protein interaction
network starting with those differentially expressed genes was
searched, where such genes were mapped in the databases with
their first neighbors. Then, we selected only the genes presented
on our array platform. To assess differences in network
organization between individuals with AD pathology versus
normal subjects, we used a nonparametric test to determine the
difference in correlation of co-expression of genes with their
interactors based on a method analogous to that previously
Transcriptional Profiles of Different Stages of AD
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described [47]. First, the Pearson Correlation Coefficient (PCC) of
each gene and its interactors for each patient group was calculated.
Then the absolute value of the difference of these PCCs was
calculated. The magnitude is the difference in PCC of a gene
between patient groups. To identify genes that are significantly
different between patient groups, we randomly assigned patients to
one of two groups and repeated the analysis. This was done 1,000
times to calculate the random distribution. Real PCC differences
for genes between patient groups were compared to the random
distribution to generate P-values (Table S2). This defines a network
signature of genes whose co-expression is different as a function of
presence or absence of AD pathology. P-value cutoff #0.05 was
considered for significance. The network was visualized using
Cytoscape [48].
Classifiers
Classifiers to separate the CP-AD and P-AD subjects were
searched. To avoid that the classifier could easily be plagued by
overfitting due the small number of individuals, we restricted to
simple classifiers, in this case linear, with only 3 genes. We also
searched for classifiers that present a small bolstered error estimate
[49,50], which was specially developed to deal with very small
sample sizes, and usually presents lower variance and bias than
traditional techniques, such as leave-one-out or cross-validation
[50]. To decrease the computational effort to analyze every
possible triplet, we used the pre-processing technique based on
linear Support Vector Machines modified to perform feature
selection [51]. After pre-processing, around 200 genes were
selected. In these genes, a full search was undertaken for triplets,
which present a good classification potential based on the
bolstered error estimate and distance to the classification surface.
Results
Gene Expression Profile Related to AD Pathology
To address which genes were related to the neuropathological
processes of AD (‘‘neuropathological AD-related genes’’,
npADGs), we compared the gene expression profile (Student’s t-
test, P#0.01) of subjects who have been histopathologically
confirmed to demonstrate pathologies associated with AD (Braak
stage $ IV and CERAD= B or C, n= 13; representing the CP-
AD and P-AD groups) and subjects without evidence of AD-
related pathology (Braak stage # II and CERAD=0 or A, n= 10;
representing the N group). A total of 77 genes were differentially
expressed - 51 were up-regulated and 26 were down-regulated in
AD pathology individuals compared to normal individuals.
Differentially expressed genes (DEGs) with their fold change and
P-values are listed in Table S3. In a subsequent step, we performed
a functional analysis that identified biological process categories
overrepresented by npADGs (Fisher’s exact test, P#0.05). The
Gene Ontology biological process categories are shown in Table 2.
Transcription factor (TF) processes were among the largest
categories of npADGs. In addition, one of the hallmarks of AD,
reduced energy metabolism, was reflected by categories of down-
regulated npADGs (CHST15, NNT, ACP5) in AD pathology
individuals, as hexose biosynthetic process, acetyl-CoA catabolic
process and negative regulation of reactive oxygen species
metabolic process. Cell adhesion/motility process, comprising
SYMN, which encodes an intermediate filament responsible for
cytoskeleton organization, DNA synthesis/repair process
(WRNIP1), and telomere maintenance process (MYC) were up-
regulated in AD pathology individuals. Further, inflammatory
processes related to IL-1 and IL-12 production (ACP5) were
overrepresented. Some DEGs, although not overrepresented in
any functional category, must be highlighted such as ITM2B that
encodes a protein involved in the inhibition and deposition of Ab
[52]; and PRKCE, encoder of protein kinase C important to
neuron channel activation, which is inhibited by amyloid beta
peptide [53].
Hierarchical Cluster Analysis
Searching for an expression pattern that could differentiate
individuals with AD histopathology from normal individuals,
a hierarchical clustering was carried out for npADGs (77 genes).
However, it was not possible to obtain a clear separation pattern
between (CP-AD + P-AD) and N groups (Figure S1).
When the hierarchical clustering was performed using npADGs
with P#0.005 (47 genes), clusters of differentially up- and down-
regulated genes were identified (Figure 1). The dendrogram shows
a discrimination pattern, with 100% of support, in two clusters: 1)
AD cluster, which grouped all CP-AD and P-AD samples (13
individuals –100%) plus 2 normal samples (2 out of 10); and 2) N
cluster, which grouped just normal samples (8 out of 10). A
functional analysis of these 47 genes keeps the overrepresented
biological processes identified with all DEGs. Using npADGs with
lower P-values, the clustering remains the same (data not shown).
Interaction Network
Aiming to explore the 47 genes identified in the clustering
analysis and their connectors an interaction network was
constructed. Genes were mapped on the human ‘‘interactome’’
and then only those in our array platform were selected (301
genes). We looked for significant differences in the average PCC of
a gene and their interacting partners in subjects who presented AD
pathology (CP-AD and P-AD groups) and those who were free of
such histopathology. This metric gives an estimate of the
difference in correlation of each interaction around a gene
between the two groups (AD pathology vs. controls). This revealed
25 genes that displayed altered PCC as a function of presence or
absence of AD neuropathology (Figure 2). For instance, one such
gene was PRKCE that has been shown to be involved with the
suppression of Ab production [54] The expression of PRKCE was
correlated in a way with the expression of its partners in AD
individuals, but changed the correlation with their expression in
normal individuals (Figure 2A).
Of the 25 significant genes identified in the network, PLP2,
ETS2, and PRKCE showed significantly differential expression
when analyzed using ‘Student’s t-test’. On the other hand, some
genes with no significant difference in the expression analysis as
BCL2, gene involved in cell death, had the co-expression of their
connectors clearly affected. Besides, genes that have not presented
significant difference of co-expression with its partners between the
two sample groups can display interesting properties, like MYC
which plays the role of an important connector gene (Figure 2B),
since it has a lot of interacting partners and connects essential parts
of the network.
Analysis of interactions between the 25 significant genes and
their partners revealed that they form an interconnected network,
and a functional analysis of these genes demonstrated over-
representation of some GO categories involved with transcrip-
tional regulation, DNA damage, inflammatory signaling, cell
adhesion, neuron differentiation, and neuron apoptosis (Table S4).
Gene Expression Profile Related to Clinical Manifestation
of AD
When individuals establish substantial neuropathological
changes of AD, some of them develop the clinical dementia
Transcriptional Profiles of Different Stages of AD
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syndrome, while others remain asymptomatic for a long period,
i.e. the preclinical stages of AD. Thus, to assess which genes might
be related to the clinical expression of AD (‘‘clinical AD-related
genes’’, cADGs), we compared the gene expression profile
(Student t-test, P,0.01) of subjects with AD pathology and clinical
dementia (CP-AD), and subjects with AD pathology but cogni-
tively normal (P-AD). We found that 23 genes were differentially
expressed between these two groups –16 were up-regulated and 7
down-regulated in CP-AD individuals compared to P-AD (Table
S5). However, taking into account the small number of DEGs, any
gene out of these 23 can be considered differentially expressed by
chance due the error of multiple testing. Therefore, a statistically
reliable change could not be detected between CP-AD and P-AD
groups.
Classifiers
As our aim was to find out transcriptional differences between
CP-AD and P-AD individuals that could not be achieved by
differential gene expressions in our study based on our small
sample size, we searched for classifiers that were able to completely
distinguish these groups utilizing another approach, which did not
consider the DEGs, but started using all the genes in the
microarray platform and applying a mathematical model design
for small sample sizes.
Six genes selected by feature selection were used to generate the
classifiers between those groups: CAPRIN1, HES1, LGR6, PTPRN,
RFC2, and ULK2. A classifier comprised by PTPRN, ULK2, and
HES1 (Figure 3A) and another classifier comprised by CAPRIN1,
ULK2, and RFC2 (Figure 3B) were able to classify 100% of
samples.
CAPRIN1 encodes a phosphoprotein required for normal
progression through the G1-S phase of the cell cycle [55], and is
expressed in post-synaptic granules in neuronal dendrites [56].
Caprin-1 likely regulates transport and translation of mRNAs of
proteins involved in synaptic plasticity in neurons [57]. HES1 is
a transcriptional repressor involved in neural development by
regulating functional aspects of neural stem cells [58]. LGR6
encodes a protein that is a glycoprotein hormone receptor. PTPRN
is a member of the protein tyrosine phosphatase (PTP) family and
represents a receptor-type PTP (RPTP). Some ligands for RPTPs
play an important role in regulating synaptogenesis and neurite
growth [59]. RFC2 is involved in DNA repair [60]. ULK2 encodes
a protein that is involved in axonal elongation [61].
Table 2. Biological process categories overrepresented by the genes related to AD neuropathology (npADGs).
regulation of transcription, DNA-dependent (P-value 0.0317) C-terminal protein amino acid modification (P-value 0.007)
zinc finger protein 266 (ZNF266) isoprenylcysteine carboxyl methyltransferase (ICMT)
general transcription factor IIH, polypeptide 1, 62 kDa (GTF2H1) plasminogen activator, urokinase receptor (PLAUR)
AF4/FMR2 family, member 3 (AFF3) RNA export from nucleus (P-value 0.0185)
zinc finger and BTB domain containing 7B (ZBTB7B) GLE1 RNA export mediator homolog (yeast) (GLE1)
helicase-like transcription factor (HLTF) RAE1 RNA export 1 homolog (S. pombe) (RAE1)
zinc finger protein 84 (ZNF84) intermediate filament cytoskeleton organization (P-value 0.0165)
zinc finger protein 576 (ZNF576) synemin, intermediate filament protein (SYNM)
transformation/transcription domain-associated protein (TRRAP) establishment of localization in cell (P-value 0.0487)
zinc finger protein 394 (ZNF394) glutamate receptor, ionotropic, kainate 5 (GRIK5)
zinc finger protein 559 (ZNF559) regulation of telomere maintenance (P-value 0.0487)
lysine (K)-specific demethylase 2B (KDM2B) v-myc myelocytomatosis viral oncogene homolog (avian) (MYC)
chromatin modification (P-value 0.0308) hexose biosynthetic process (P-value 0.0327)
helicase-like transcription factor (HLTF) carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 (CHST15)
ubiquitin-conjugating enzyme E2A (UBE2A) DNA synthesis involved in DNA repair (P-value 0.0327)
transformation/transcription domain-associated protein (TRRAP) Werner helicase interacting protein 1 (WRNIP1)
lysine (K)-specific demethylase 2B (KDM2B) negative regulation of reactive oxygen species metabolic process (P-value
0.0487)
mRNA transport (P-value 0.0075) acid phosphatase 5, tartrate resistant (ACP5)
nucleoporin 50 kDa (NUP50) acetyl-CoA catabolic process (P-value 0.0327)
GLE1 RNA export mediator homolog (yeast) (GLE1) nicotinamide nucleotide transhydrogenase (NNT)
RAE1 RNA export 1 homolog (S. pombe) (RAE1) regulation of synaptic vesicle exocytosis (P-value 0.0165)
hexose transport (P-value 0.0158) glutamate receptor, ionotropic, kainate 5 (GRIK5)
nucleoporin 50 kDa (NUP50) negative regulation of interleukin-1 production (P-value 0.0327)
RAE1 RNA export 1 homolog (S. pombe) (RAE1) acid phosphatase 5, tartrate resistant (ACP5)
protein targeting to membrane (P-value 0.0089)
isoprenylcysteine carboxyl methyltransferase (ICMT)
translocase of inner mitochondrial membrane 9 homolog (yeast) (TIMM9)
Biological process categories significantly overrepresented by npADGs (P,0.05, Fisher’s exact test). Other similar significant categories are not included to reduce
redundancy.
doi:10.1371/journal.pone.0048751.t002
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Figure 1. Hierarchical clustering analysis of CP-AD, P-AD and N samples. Hierarchical clustering was performed by using the expression
values from the genes related to AD neuropathology with P#0.005 (47 transcripts). Each row represents a single gene and each column a sample
(dark blue, CP-AD samples; light blue, P-AD samples; yellow, N samples). Red indicates upregulation, green indicates downregulation, and black
indicates no change in expression level comparing to reference sample. Cluster support was given by Bootstrap technic (black, 100% of support; grey,
90–100%; blue, 80–90%; green, 70–80%; light yellow, 60–70%; dark yellow, 50–60%; magenta, 0–50%, red, 0%). CP-AD, clinic-pathological Alzheimer’s
disease; P-AD, pathological/preclinical Alzheimer’s disease; N, normal samples (controls).
doi:10.1371/journal.pone.0048751.g001
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Discussion
Microarray studies comparing AD subjects with normal elderly
individuals have uncovered multiple pathophysiological processes
that have been implicated in AD, including energy metabolism
[15], transcriptional and tumor suppressor responses [16],
apoptosis, inflammation [17], cholinergic activity [18], calcium
signaling [19], lipid metabolism [20], and synaptic dysfunction and
neuroplasticity [21,22]. In the present study, we included a group
of subjects with preclinical AD - a period during which there are
abundant amyloid deposits and neurofibrillary tangles in the brain
but no evidence of cognitive decline - to provide further support to
the relevance of genes involved in the early development of
neurodegenerative changes in AD.
The AD neuropathology-related gene set was involved in some
important functions suspected of a role in AD and brain aging, in
particular energy metabolism and oxidative stress (hexose trans-
port, hexose biosynthetic process, acetyl-CoA catabolic process,
negative regulation of reactive oxygen species metabolic process),
immune function (negative regulation of interleukin-1 production),
Figure 2. Interaction networks of the significant genes and their interacting partners. (A) Shown are the genes (color nodes) that have, as
a function of presence (CP-AD + P-AD) or absence (N) of AD pathology, significantly different correlation of co-expression with their partners. Green
nodes indicate genes that are significantly differently expressed between patient groups, while light blue nodes indicate genes that are not
significantly differently expressed. Edge colors represent the correlation between a gene and each of its partners. (B) MYC and its interacting partners.
Note that the significant genes and their partners form an interconnected network, and despite the interactions involving MYC are not significantly
altered, it has a lot of connections, playing an important role as a hub gene. CP-AD, clinic-pathological Alzheimer’s disease; P-AD, pathological/
preclinical Alzheimer’s disease; N, normal samples (controls).
doi:10.1371/journal.pone.0048751.g002
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DNA repair (DNA synthesis involved in DNA repair), senescence
(regulation of telomere maintenance) and transcriptional regula-
tion (regulation of transcription, DNA-dependent, and chromatin
modification). We have to consider that these functions/gene
expression might be disrupted as an early response to the increased
accumulation of Ab peptide and tau observed in the CP-AD and
P-AD individuals [62].
Glucose metabolism is impaired in AD brain [63], and the
decreased neuronal glucose metabolism has been associated with
tau hyperphosphorylation [64]. Moreover, histopathological
alterations of AD also induce functional deficits of the respiratory
chain complexes and therefore consecutively result in mitochon-
drial dysfunction and oxidative stress [65,66]. In consequence to
the oxidative stress, markers of DNA damage, particularly
oxidative DNA damage, have been largely found in brain regions
of AD patients. Brain in AD might be subjected to the double
insult of increased DNA damage, as well as deficiencies of DNA
repair pathways [67]. As regards to telomere maintenance, several
studies have addressed the importance of MYC in regulating the
expression of telomerase [68]. We found MYC up-regulated in AD
pathology-carrier individuals, which could cause overexpression of
telomerase leading to an accentuated ageing cell in such subjects.
In relation to immune/inflammatory response, Ab has proin-
flammatory actions, including the activation of microglia and
stimulating their production and release of inflammatory factors
such as IL-1 [69]. Interestingly, the synthesis of amyloid precursor
protein (APP), and its cleavage resulting in Ab peptide, are
stimulated by IL-1 [70,71]. Notably, IL-1 also seems to be
implicated with the neurofibrillary tangles, participating at the
hyperphosphorylation of tau protein [72]. Of note, Liang et al.
[73], comparing neurons of non-demented individuals who
demonstrate intermediate levels of AD pathology (Braak stage of
II to IV with a CERAD neuritic plaque density of moderate or
frequent – similar to P-AD group, but in our case such individuals
Figure 3. Multivariate (three-gene) discriminators for Alzheimer’s disease (AD) classification. (A) Discriminator of CP-AD samples (blue)
and P-AD samples (red) using the expression values of PTPRN, ULK2, and HES1 genes. (B) Discriminator of CP-AD samples (blue) and P-AD samples
(red) using the expression values of CAPRIN1, ULK2, and RFC2 genes. CP-AD, clinic-pathological Alzheimer’s disease; P-AD, pathological/preclinical
Alzheimer’s disease.
doi:10.1371/journal.pone.0048751.g003
Figure 4. Hypothetical model of the gene expression alterations related to neuropathology and clinical manifestation of
Alzheimer’s disease (AD). Gene expression profile changes related to AD pathology are implicated with energy metabolism, oxidative stress, DNA
damage and transcriptional regulation. Once established of significant AD pathology, some genes involved with synaptic plasticity, and cell cycle
appear to be involved with the clinical outcome of the illness and might represent the molecular mechanisms that underlie the cognitive reserve. CP-
AD, clinic-pathological Alzheimer’s disease; P-AD, pathological/preclinical Alzheimer’s disease.
doi:10.1371/journal.pone.0048751.g004
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present high level of pathology) vs. control brains and AD vs.
control brains, found common expression changes related to
formation of NFTs and amyloid plaques.
From the AD pathology-related DEGs (77 genes), we also
identified a gene set (47 genes) providing two clear patterns
between individuals with neuropathology and normal subjects.
These 47 genes were utilized to construct an interaction network.
Network science deals with complexity by ‘‘simplifying’’ complex
systems, summarizing them merely as components (nodes) and
interactions (edges) between them. The resulting ‘‘interactome’’,
the networks of interactions between cellular components, can
serve as scaffold information to extract global or local graph theory
properties. Once shown to be statistically different from random-
ized networks, such properties can then be related back to a better
understanding of biological processes [74]. Our interaction
network revealed 25 genes and their interactors that showed
significant alterations of co-expression of components. Thus, we
were able to identify important changes in the network that are
associated with the AD neuropathology. An advantage of this
approach is the capacity to reveal important genes that were not
identified by conventional statistical tests. Furthermore, we could
extract some properties of the network, like an important
connector gene (hub) represented by MYC.
Regarding to genes related to clinical manifestation of dementia
in brains with substantial AD histopathology, we compared
individuals that have been clinically and histopathologically
confirmed to have AD (CP-AD) with individuals who did not
fulfill clinical criteria for AD but demonstrate high levels of AD-
related pathology (P-AD). With the bias of a limited statistical
power, a reliable expression change could not be detected, and so,
CP-AD and P-AD were transcriptionally indistinguishable using
a statistical test with this small sample size.
However, we utilized a classification approach, which does not
consider the differentially expressed genes, but it starts with all
genes of the array platform, to discriminate CP-AD and P-AD
individuals. Disease classification is another approach already used
in the molecular diagnosis and classification of several illnesses,
including AD [75,76]. We found 6 genes capable to separate CP-
AD from P-AD individuals. Interestingly, these genes were related
to biological functions that have been widely associated with AD,
as synaptic plasticity [77–80], and cell cycle [81,82], suggesting
them as important pathways on the clinical emergence of the
disease. Although we have used a well-established error estimation
technique to select good genes and to design classifiers for a small
number of samples, we understand that classification approach
provides candidates for further validation.
Therefore, we have added some evidence to a hypothesis model
in which relatively independent processes contribute to the AD
pathology and AD clinical manifestation (Figure 4). The patho-
logical changes are linked to energy metabolism, oxidative stress,
DNA damage/repair, senescence and transcriptional regulation.
Once developed substantial AD-related pathology, the transcrip-
tional profile between demented and non-demented individuals is
very similar, although some genes implicated with synaptic
plasticity, and cell cycle might be involved in the clinical
manifestation of dementia, requiring further investigations about
the roles of these pathways in such subjects. It is relevant to
highlight that, since subjects with high burden of histopathological
lesions can support them without cognitive decline, the identifi-
cation of transcriptional alterations in relation to symptomatic AD
individuals may help to uncover the molecular basis underlying
the cognitive reserve [83]. Another microarray study comparing
AD cases and non-demented individuals with AD pathology
suggests an immune dysfunction between those groups [84].
Comparing neurons of non-demented individuals with intermedi-
ate levels of AD pathology vs. control brains and AD vs. control
brains, Liang et al. [73] identified exclusive expression changes
related to learning/memory processes in non-demented individ-
uals with AD vs. control comparison, representing possible
compensatory efforts targeted against onset of cognitive deficits.
Limitations of this work are comprised by both small sample size
and gender unbalance. Searching the DEGs taking out men or
women, as in leave-one-out analysis, the final list of genes presents
variations independently of gender (data not shown). To overcome
these limitations, we used different approaches to find relevant
genes: 1) hierarchical clustering and network analysis using DEGs,
and 2) classification analysis, not using the DEGs, but starting with
all genes in the array.
Further studies with larger sample sizes are necessary to better
understand the pathogenic mechanisms of early stages of AD, and
to discover pre-clinical biomarkers and rational therapeutic
targets. To this end, studies with pre-symptomatic animal models
could be of extreme importance on developing of time or stage-
dependent interventions to achieve optimal results in delaying the
progression of AD-related pathological changes or clinical
symptoms of dementia.
Supporting Information
Figure S1 Hierarchical clustering was performed by
using the expression values from the genes related to AD
neuropathology (77 transcripts with P#0.01). Each row
represents a single gene and each column a sample (dark blue, CP-
AD samples; light blue, P-AD samples; yellow, N samples). Red
indicates upregulation, green indicates downregulation, and black
indicates no change in expression level comparing to reference
sample. The cluster support was given by Bootstrap technic (black,
100% of support; grey, 90–100%; blue, 80–90%; green, 70–80%;
light yellow, 60–70%; dark yellow, 50–60%; magenta, 0–50%,
red, 0%). CP-AD, clinic-pathological Alzheimer’s disease; P-AD,
pathological/preclinical Alzheimer’s disease; N, normal samples
(controls).
(TIF)
Table S1 Yield and purity of total and amplified RNA.
RNA purity and yield were determined by UV spectrophotometry.
Yield is given in mg and purity was assessed by absorbance at 260/
280 nm. CP-AD, clinic-pathological Alzheimer’s disease; P-AD,
pathological/preclinical Alzheimer’s disease; N, normal individu-
als (controls).
(PDF)
Table S2 Data of interaction network analysis. To
determine the genes and their interactors that significantly
discriminate between individuals who demonstrate AD pathology
versus those without such lesions we used a non-parametric test.
Each gene was assessed for the difference of the Pearson
Correlation Coefficient (PCC) of each interaction. Then, the
average difference of the absolute value (avg_abs_diff) for the gene
and each of interactors was calculated. To determine if the
deviation in correlation between the two groups is significant we
randomly reassigned the patients to the two groups 1000 times and
recalculated the avg_abs_diff. Therefore, the p-value of each gene
was given as the frequency of the random avg_abs_diff being
greater than the real avg_abs_diff divided by 1000. Original_av-
g_abs_diff, real average difference of the absolute value of PCCs
between (CP-AD + P-AD) vs. N; Degree, number of connectors of
a node (gene); Times_greater (in 1000), frequency of the random
avg_abs_diff being greater than the real avg_abs_diff.
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(PDF)
Table S3 Identification of the differentially expressed
genes related to AD neuropathology (npADGs). Genes
identified by Student’s t-test are listed according to P-value and the
fold change of gene level from the clinic-pathological AD samples
+ pathological/preclinical AD samples (CP-AD + P-AD) com-
pared to normal samples (N). Genes were considered differentially
expressed at P-values of #0.01. Abbreviations: ORESTES, Open
Reading Frame Expressed Sequence Tags identification. Gene-
Bank, accession number at the GeneBank. Entrez Gene, accession
number at the Entrez Gene.
(PDF)
Table S4 Biological process categories overrepresented
by the genes related to interaction network. Biological
process categories significantly overrepresented by significant
genes and their connectors from the interaction network
(P#0.05, Fisher’s exact test). Other similar significant categories
are not included to reduce redundancy.
(PDF)
Table S5 Identification of the differentially expressed
genes related to clinical manifestation of AD (cADGs).
Genes identified by Student’s t-test are listed according to fold
change of gene level and P-value from the clinic-pathological AD
samples (CP-AD) compared to pathological/preclinical AD
samples (P-AD). Genes were considered differentially expressed
at P#0.01. Abbreviations: ORESTES, Open Reading Frame
Expressed Sequence Tags identification. GeneBank, accession
number at the GeneBank. Entrez Gene, accession number at the
Entrez Gene.
(PDF)
Acknowledgments
We thank Louise Danielle Mota, Waleska Martins, and Elen Bastos for
technical assistance with the experimental procedures.
Author Contributions
Conceived and designed the experiments: HB LG JF BD. Performed the
experiments: AS. Analyzed the data: AS LL PS HB. Contributed reagents/
materials/analysis tools: RR DC WF RF. Wrote the paper: AS BD HB.
References
1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:
387–403.
2. Hardy J, Selkoe D (2002) The amyloid hypothesis of Alzheimer’s disease:
progress and problems on the road to therapeutics. Science 297: 353–356.
3. Iqbal K, Alonso AC, Chen S, Chohan M, El-Akkad E, et al. (2005) Tau
pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta
1739: 198–210.
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984)
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work
Group under the auspices of Department of Health and Human Services Task
Force on Alzheimer’s Disease. Neurology 34: 939–944.
5. Mirra S, Heyman A, McKeel D, Sumi S, Crain B, et al. (1991) The Consortium
to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standard-
ization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:
479–486.
6. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology
of Alzheimer’s disease. Trends Pharmacol Sci 12: 383–388.
7. Selkoe DJ (1991) The molecular pathology of Alzheimer’s disease. Neuron 6:
487–498.
8. Price J, Morris J (1999) Tangles and plaques in nondemented aging and
‘‘preclinical’’ Alzheimer’s disease. Ann Neurol 45: 358–368.
9. Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, et al. (2009)
Neuropathology of nondemented aging: presumptive evidence for preclinical
Alzheimer disease. Neurobiol Aging 30: 1026–1036.
10. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, et al. (2007)
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive
decline in nondemented older adults. Arch Neurol 64: 343–349.
11. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, et al. (2009) Decreased
cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal
elderly. Ann Neurol 65: 176–183.
12. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, et al. (2008) Abeta
deposits in older non-demented individuals with cognitive decline are indicative
of preclinical Alzheimer’s disease. Neuropsychologia 46: 1688–1697.
13. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, et al. (2008)
Frequent amyloid deposition without significant cognitive impairment among
the elderly. Arch Neurol 65: 1509–1517.
14. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. (2011) Toward
defining the preclinical stages of Alzheimer’s disease: recommendations from the
National Institute on Aging-Alzheimer’s Association workgroups on diagnostic
guidelines for Alzheimer’s disease. Alzheimers Dement 7: 280–292.
15. Brooks W, Lynch P, Ingle C, Hatton A, Emson P, et al. (2007) Gene expression
profiles of metabolic enzyme transcripts in Alzheimer’s disease. Brain Res 1127:
127–135.
16. Blalock E, Geddes J, Chen K, Porter N, Markesbery W, et al. (2004) Incipient
Alzheimer’s disease: microarray correlation analyses reveal major transcriptional
and tumor suppressor responses. Proc Natl Acad Sci U S A 101: 2173–2178.
17. Colangelo V, Schurr J, Ball M, Pelaez R, Bazan N, et al. (2002) Gene expression
profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and
neurotrophic factor down-regulation and up-regulation of apoptotic and pro-
inflammatory signaling. J Neurosci Res 70: 462–473.
18. Counts S, He B, Che S, Ikonomovic M, DeKosky S, et al. (2007) Alpha7
nicotinic receptor up-regulation in cholinergic basal forebrain neurons in
Alzheimer disease. Arch Neurol 64: 1771–1776.
19. Emilsson L, Saetre P, Jazin E (2006) Alzheimer’s disease: mRNA expression
profiles of multiple patients show alterations of genes involved with calcium
signaling. Neurobiol Dis 21: 618–625.
20. Katsel P, Li C, Haroutunian V (2007) Gene expression alterations in the
sphingolipid metabolism pathways during progression of dementia and
Alzheimer’s disease: a shift toward ceramide accumulation at the earliest
recognizable stages of Alzheimer’s disease? Neurochem Res 32: 845–856.
21. Williams C, Mehrian Shai R, Wu Y, Hsu Y, Sitzer T, et al. (2009)
Transcriptome analysis of synaptoneurosomes identifies neuroplasticity genes
overexpressed in incipient Alzheimer’s disease. PLoS One 4: e4936.
22. Yao P, Zhu M, Pyun E, Brooks A, Therianos S, et al. (2003) Defects in
expression of genes related to synaptic vesicle trafficking in frontal cortex of
Alzheimer’s disease. Neurobiol Dis 12: 97–109.
23. Diniz BS, Teixeira AL, Ojopi EB, Talib LL, Mendonc¸a VA, et al. (2010) Higher
serum sTNFR1 level predicts conversion from mild cognitive impairment to
Alzheimer’s disease. J Alzheimers Dis 22: 1305–1311.
24. Forlenza OV, Diniz BS, Gattaz WF (2010) Diagnosis and biomarkers of
predementia in Alzheimer’s disease. BMC Med 8: 89.
25. Forlenza OV, Diniz BS, Teixeira AL, Ojopi EB, Talib LL, et al. (2010) Effect of
brain-derived neurotrophic factor Val66Met polymorphism and serum levels on
the progression of mild cognitive impairment. World J Biol Psychiatry 11: 774–
780.
26. Gattaz WF, Forlenza OV, Talib LL, Barbosa NR, Bottino CM (2004) Platelet
phospholipase A(2) activity in Alzheimer’s disease and mild cognitive
impairment. J Neural Transm 111: 591–601.
27. Cenini G, Sultana R, Memo M, Butterfield DA (2008) Elevated levels of pro-
apoptotic p53 and its oxidative modification by the lipid peroxidation product,
HNE, in brain from subjects with amnestic mild cognitive impairment and
Alzheimer’s disease. J Cell Mol Med 12: 987–994.
28. Swerdlow RH, Khan SM (2004) A ‘‘mitochondrial cascade hypothesis’’ for
sporadic Alzheimer’s disease. Med Hypotheses 63: 8–20.
29. Galindo MF, Ikuta I, Zhu X, Casadesus G, Jorda´n J (2010) Mitochondrial
biology in Alzheimer’s disease pathogenesis. J Neurochem 114: 933–945.
30. Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, et al.
(2010) Soluble TNF receptors are associated with Abmetabolism and conversion
to dementia in subjects with mild cognitive impairment. Neurobiol Aging 31:
1877–1884.
31. Schaub RT, Anders D, Golz G, Go¨hringer K, Hellweg R (2002) Serum nerve
growth factor concentration and its role in the preclinical stage of dementia.
Am J Psychiatry 159: 1227–1229.
32. Go´mez Ravetti M, Rosso OA, Berretta R, Moscato P (2010) Uncovering
molecular biomarkers that correlate cognitive decline with the changes of
hippocampus’ gene expression profiles in Alzheimer’s disease. PLoS One 5:
e10153.
33. Podtelezhnikov AA, Tanis KQ, Nebozhyn M, Ray WJ, Stone DJ, et al. (2011)
Molecular insights into the pathogenesis of Alzheimer’s disease and its
relationship to normal aging. PLoS One 6: e29610.
34. Ferretti REL, Damin AE, Brucki SMD, Morillo LS, Perroco TR, et al. (2010)
Post-Mortem diagnosis of dementia by informant interview. Dement Neurop-
sychol 4: 138–144.
35. Morris J (1993) The Clinical Dementia Rating (CDR): current version and
scoring rules. Neurology 43: 2412–2414.
Transcriptional Profiles of Different Stages of AD
PLOS ONE | www.plosone.org 10 November 2012 | Volume 7 | Issue 11 | e48751
36. Grinberg L, Ferretti R, Farfel J, Leite R, Pasqualucci C, et al. (2007) Brain bank
of the Brazilian aging brain study group - a milestone reached and more than
1,600 collected brains. Cell Tissue Bank 8: 151–162.
37. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol 82: 239–259.
38. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, et al. (2009)
Episodic memory loss is related to hippocampal-mediated beta-amyloid
deposition in elderly subjects. Brain 132: 1310–1323.
39. Gomes L, Silva R, Stolf B, Cristo E, Hirata R, et al. (2003) Comparative analysis
of amplified and nonamplified RNA for hybridization in cDNA microarray.
Anal Biochem 321: 244–251.
40. Pollack J (2003) RNA Common Reference Sets. In: Botwell D, editor. DNA
microarrays: a molecular cloning manual. Cold Spring Harbor, N.Y.: Cold
Spring Harbor Press. 168–172.
41. Dias Neto E, Correa R, Verjovski-Almeida S, Briones M, Nagai M, et al. (2000)
Shotgun sequencing of the human transcriptome with ORF expressed sequence
tags. Proc Natl Acad Sci U S A 97: 3491–3496.
42. Saeed A, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-
source system for microarray data management and analysis. Biotechniques 34:
374–378.
43. Prifti E, Zucker J, Clement K, Henegar C (2008) FunNet: an integrative tool for
exploring transcriptional interactions. Bioinformatics 24: 2636–2638.
44. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, et al.
(2009) Human Protein Reference Database–2009 update. Nucleic Acids Res 37:
D767–772.
45. Licata L, Briganti L, Peluso D, Perfetto L, Iannuccelli M, et al. (2012) MINT,
the molecular interaction database: 2012 update. Nucleic Acids Res 40: D857–
861.
46. Kerrien S, Aranda B, Breuza L, Bridge A, Broackes-Carter F, et al. (2012) The
IntAct molecular interaction database in 2012. Nucleic Acids Res 40: D841–
846.
47. Taylor IW, Linding R, Warde-Farley D, Liu Y, Pesquita C, et al. (2009)
Dynamic modularity in protein interaction networks predicts breast cancer
outcome. Nat Biotechnol 27: 199–204.
48. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, et al. (2007)
Integration of biological networks and gene expression data using Cytoscape.
Nat Protoc 2: 2366–2382.
49. Kim S, Dougherty E, Barrera J, Chen Y, Bittner M, et al. (2002) Strong feature
sets from small samples. J Comput Biol 9: 127–146.
50. Braga-Neto U, Dougherty E (2004) Bolstered error estimation. Pattern Recognit
37: 1267–1281.
51. Silva P, Hashimoto R, Kim S, Barrera J, Brandao L, et al. (2005) Feature
selection algorithms to find strong genes. Pattern Recognit Lett 26: 1444–1453.
52. Peng S, Fitzen M, Jo¨rnvall H, Johansson J (2010) The extracellular domain of
Bri2 (ITM2B) binds the ABri peptide (1–23) and amyloid beta-peptide (Abeta1–
40): Implications for Bri2 effects on processing of amyloid precursor protein and
Abeta aggregation. Biochem Biophys Res Commun 393: 356–361.
53. Lee W, Boo JH, Jung MW, Park SD, Kim YH, et al. (2004) Amyloid beta
peptide directly inhibits PKC activation. Mol Cell Neurosci 26: 222–231.
54. Zhu G, Wang D, Lin YH, McMahon T, Koo EH, et al. (2001) Protein kinase C
epsilon suppresses Abeta production and promotes activation of alpha-secretase.
Biochem Biophys Res Commun 285: 997–1006.
55. Wang B, David M, Schrader J (2005) Absence of caprin-1 results in defects in
cellular proliferation. J Immunol 175: 4274–4282.
56. Shiina N, Shinkura K, Tokunaga M (2005) A novel RNA-binding protein in
neuronal RNA granules: regulatory machinery for local translation. J Neurosci
25: 4420–4434.
57. Solomon S, Xu Y, Wang B, David M, Schubert P, et al. (2007) Distinct
structural features of caprin-1 mediate its interaction with G3BP-1 and its
induction of phosphorylation of eukaryotic translation initiation factor 2alpha,
entry to cytoplasmic stress granules, and selective interaction with a subset of
mRNAs. Mol Cell Biol 27: 2324–2342.
58. Kageyama R, Ohtsuka T, Kobayashi T (2008) Roles of Hes genes in neural
development. Dev Growth Differ 50 Suppl 1: S97–103.
59. Tonks N (2006) Protein tyrosine phosphatases: from genes, to function, to
disease. Nat Rev Mol Cell Biol 7: 833–846.
60. Tomida J, Masuda Y, Hiroaki H, Ishikawa T, Song I, et al. (2008) DNA
damage-induced ubiquitylation of RFC2 subunit of replication factor C
complex. J Biol Chem 283: 9071–9079.
61. Tomoda T, Kim J, Zhan C, Hatten M (2004) Role of Unc51.1 and its binding
partners in CNS axon outgrowth. Genes Dev 18: 541–558.
62. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al. (2010)
Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological
cascade. Lancet Neurol 9: 119–128.
63. Hoyer S (2004) Causes and consequences of disturbances of cerebral glucose
metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp
Med Biol 541: 135–152.
64. Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX (2008) Decreased glucose
transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer
disease. FEBS Lett 582: 359–364.
65. Hauptmann S, Scherping I, Dro¨se S, Brandt U, Schulz KL, et al. (2009)
Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates
with age in AD transgenic mice. Neurobiol Aging 30: 1574–1586.
66. Mohmmad Abdul H, Sultana R, Keller JN, St Clair DK, Markesbery WR, et al.
(2006) Mutations in amyloid precursor protein and presenilin-1 genes increase
the basal oxidative stress in murine neuronal cells and lead to increased
sensitivity to oxidative stress mediated by amyloid beta-peptide (1–42), HO and
kainic acid: implications for Alzheimer’s disease. J Neurochem 96: 1322–1335.
67. Coppede` F, Migliore L (2009) DNA damage and repair in Alzheimer’s disease.
Curr Alzheimer Res 6: 36–47.
68. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, et al. (2000) Sp1 cooperates
with c-Myc to activate transcription of the human telomerase reverse
transcriptase gene (hTERT). Nucleic Acids Res 28: 669–677.
69. Lindberg C, Selenica ML, Westlind-Danielsson A, Schultzberg M (2005) Beta-
amyloid protein structure determines the nature of cytokine release from rat
microglia. J Mol Neurosci 27: 1–12.
70. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, et al. (1992)
Cholinergic agonists and interleukin 1 regulate processing and secretion of the
Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci U S A 89:
10075–10078.
71. Del Bo R, Angeretti N, Lucca E, De Simoni MG, Forloni G (1995) Reciprocal
control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production
in cultures. Neurosci Lett 188: 70–74.
72. Sheng JG, Zhu SG, Jones RA, Griffin WS, Mrak RE (2000) Interleukin-1
promotes expression and phosphorylation of neurofilament and tau proteins
in vivo. Exp Neurol 163: 388–391.
73. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, et al. (2010)
Neuronal gene expression in non-demented individuals with intermediate
Alzheimer’s Disease neuropathology. Neurobiol Aging 31: 549–566.
74. Vidal M, Cusick ME, Baraba´si AL (2011) Interactome networks and human
disease. Cell 144: 986–998.
75. Nagasaka Y, Dillner K, Ebise H, Teramoto R, Nakagawa H, et al. (2005) A
unique gene expression signature discriminates familial Alzheimer’s disease
mutation carriers from their wild-type siblings. Proc Natl Acad Sci U S A 102:
14854–14859.
76. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, et al. (2007)
Classification and prediction of clinical Alzheimer’s diagnosis based on plasma
signaling proteins. Nat Med 13: 1359–1362.
77. Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298: 789–791.
78. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, et al. (1991) Physical
basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major
correlate of cognitive impairment. Ann Neurol 30: 572–580.
79. Williams C, Mehrian Shai R, Wu Y, Hsu YH, Sitzer T, et al. (2009)
Transcriptome analysis of synaptoneurosomes identifies neuroplasticity genes
overexpressed in incipient Alzheimer’s disease. PLoS One 4: e4936.
80. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008)
Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair
synaptic plasticity and memory. Nat Med 14: 837–842.
81. Yang Y, Mufson EJ, Herrup K (2003) Neuronal cell death is preceded by cell
cycle events at all stages of Alzheimer’s disease. J Neurosci 23: 2557–2563.
82. Yang Y, Herrup K (2007) Cell division in the CNS: protective response or lethal
event in post-mitotic neurons? Biochim Biophys Acta 1772: 457–466.
83. Stern Y (2006) Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc
Disord 20: S69–74.
84. Parachikova A, Agadjanyan M, Cribbs D, Blurton-Jones M, Perreau V, et al.
(2007) Inflammatory changes parallel the early stages of Alzheimer disease.
Neurobiol Aging 28: 1821–1833.
Transcriptional Profiles of Different Stages of AD
PLOS ONE | www.plosone.org 11 November 2012 | Volume 7 | Issue 11 | e48751
